Every clinical trial presents challenges, no matter the therapeutic area. But rare disease trials are especially difficult due to the sparsity of the patient population, knowledge gaps in the research community, and a lack of study funding, among other difficulties.
These obstacles are why rare disease trials are almost
70% more likely
than other trials to face a major delay.
Speed and agility make the difference
Speed and agility make the difference
The good news: Although rare disease clinical trials have their own specific requirements, they share a common set of challenges. At Biorasi’s Rare Disease Center of Excellence, we set out to solve those challenges and deliver successful rare disease clinical trials on time.
Fast, responsive, and flexible
Fast, responsive, and flexible
Over nearly 20 years, Biorasi has meticulously built a team and operating model with the capability to keep your study moving rapidly. And nowhere is that distinction more important than in rare diseases.
Rare Disease Center of Excellence
Led by Marc Gas, PhD, Biorasi’s Rare Disease Center of Excellence features clinical and operational expertise backed by our own Scientific Advisory Board of industry experts and KOLs. When you choose Biorasi as your CRO, you are choosing an industry leader that meets your rare disease clinical trial goals successfully.
Biorasi’s speed and agility make the difference overcoming common obstacles in rare disease clinical trials:
